title: Topical cyclosporin A in the treatment of anterior segment inflammatory disease.
abstract: Topical cyclosporin A was used in the management of 43 patients with a variety of anterior segment inflammatory disorders that had failed corticosteroid treatment. Treatment with topical cyclosporin A ranged from 1 week to 43 months, with a mean treatment period of 13 months. Thirty-five patients (81%) with disorders including high-risk keratoplasty, atopic and vernal keratoconjunctivitis, ligneous conjunctivitis, ulcerative keratitis, and Mooren's ulcer had a beneficial result, with resolution, reduction, or prevention of inflammation. Six patients (14%) with scleritis, ocular cicatricial pemphigoid, or endothelitis showed no clinical improvement. Two patients (5%) had significant ocular discomfort, and the drug had to be discontinued in them. None of the other patients developed local side effects. Twenty-seven of these patients were followed with serial cyclosporin A blood levels and serum creatinine. None of these patients developed measurable drug blood levels or renal toxicity.
authors.affiliation: Department of Ophthalmology, University of Minnesota, Minneapolis 55455.
authors.forename: E J
authors.initials: EJ
authors.lastname: Holland
authors.forename: T W
authors.initials: TW
authors.lastname: Olsen
authors.forename: J M
authors.initials: JM
authors.lastname: Ketcham
authors.forename: C
authors.initials: C
authors.lastname: Florine
authors.forename: J H
authors.initials: JH
authors.lastname: Krachmer
authors.forename: J J
authors.initials: JJ
authors.lastname: Purcell
authors.forename: S
authors.initials: S
authors.lastname: Lam
authors.forename: H H
authors.initials: HH
authors.lastname: Tessler
authors.forename: J
authors.initials: J
authors.lastname: Sugar
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000869:Anterior Eye Segment / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D003315:Cornea / Q000187:drug effects; D016572:Cyclosporine / Q000008:administration & dosage* / Q000627:therapeutic use; D009877:Endophthalmitis / Q000188:drug therapy*; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions
chemical_list: D009883:Ophthalmic Solutions; D016572:Cyclosporine